Interaction of Bortezomib with Cell Membranes Regulates Its Toxicity and Resistance to Therapy

Bortezomib (BTZ) is a potent proteasome inhibitor currently being used to treat multiple myeloma. However, its high toxicity and resistance to therapy severely limit the treatment outcomes. Drug–membrane interactions have a crucial role in drugs’ behavior in vivo, affecting their bioavailability and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramalho, Maria João, Andrade, Stéphanie, Loureiro, Joana Angélica, Pereira, Maria Carmo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500884/
https://www.ncbi.nlm.nih.gov/pubmed/36135842
http://dx.doi.org/10.3390/membranes12090823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500884/
https://www.ncbi.nlm.nih.gov/pubmed/36135842
http://dx.doi.org/10.3390/membranes12090823

Ejemplares similares